Siddarth Subramony - May 29, 2024 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Stock symbol
TYRA
Transactions as of
May 29, 2024
Transactions value $
$0
Form type
4
Date filed
5/31/2024, 04:30 PM
Previous filing
Jun 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Award $0 +18.6K $0.00 18.6K May 29, 2024 Common Stock 18.6K $15.94 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 29, 2024, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F2 These securities are owned directly by the Reporting Person, who may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, LLC, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC, (iv) Joseph C. Lewis, (v) Aaron Davis and (vi) the Reporting Person (collectively, the "Boxer Group"). Each member of the Boxer Group other than the Reporting Person disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein